Fibronostics

Executive Summary

Fibronostics is a US-based digital diagnostics company transforming liver disease management with its flagship product, LIVERFASt™. This non-invasive, AI-driven blood test accurately stages liver fibrosis, activity, and steatosis, offering a safer, cost-effective alternative to invasive biopsies. Targeting the growing metabolic liver disease epidemic (MASLD/MASH), Fibronostics addresses a critical unmet need: early detection and monitoring without procedural risks. With over 25% of the global adult population affected by fatty liver disease, the company's technology could significantly reduce healthcare costs and improve patient outcomes. LIVERFASt has already demonstrated strong clinical performance in validation studies, positioning Fibronostics for commercial expansion. The company is well-positioned to capture a share of the multi-billion-dollar liver diagnostics market, pending regulatory milestones and strategic partnerships. A successful commercialization would disrupt the standard of care, enabling widespread screening and personalized treatment monitoring for chronic liver conditions.

Upcoming Catalysts (preview)

• Q2 2026FDA 510(k) Clearance for LIVERFASt70% success
• Q3 2026Large-Scale Multicenter Clinical Validation Study Publication80% success
• Q4 2026Strategic Partnership with Major Health System for Commercial Rollout50% success